This is a working overview of PPARδ, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-27 and is reviewed periodically as new material appears.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
== Structural studies == As of late 2007, 8 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1OPM, PDB: 1PHM, PDB: 1SDW, PDB: 1YI9, PDB: 1YIP, PDB: 1YJK, PDB: 1YJL, and PDB: 3PHM.
=== Two-step mechanism – autocatalysis model === In 1997, Finke and Watzky proposed a new kinetic model for the nucleation and growth of nanoparticles. This 2-step model suggested that constant slow nucleation (occurring far from supersaturation) is followed by autocatalytic growth where dispersity of nanoparticles is largely determined. This F-W (Finke-Watzky) 2-step model provides a firmer mechanistic basis for the design of nanoparticles with a focus on size, shape, and dispersity control. The model was later expanded to a 3-step and two 4-step models between 2004 and 2008. Here, an additional step was included to account for small particle aggregation, where two smaller particles could aggregate to form a larger particle. Next, a fourth step (another autocatalytic step) was added to account for a small particle agglomerating with a larger particle. Finally in 2014, an alternative fourth step was considered that accounted for a atomistic surface growth on a large particle.
The Humr are one of the tribes in the Baggara ethnic group, native to southwestern Kordofan in Sudan who speak Shuwa (Chadian Arabic), make a non-alcoholic drink from the liver and bone marrow of the giraffe, which they call umm nyolokh. They claim it is intoxicating (Arabic سكران sakran), causing dreams and even waking hallucinations. Anthropologist Ian Cunnison accompanied the Humr on one of their giraffe-hunting expeditions in the late 1950s, and noted that:
Sources: en.wikipedia.org
=== 2.0 === On 26 June 2019, VESA formally released the DisplayPort 2.0 standard. VESA stated that version 2.0 is the first major update to the DisplayPort standard since March 2016, and provides up to a ≈3× improvement in data rate (from 25.92 to 77.37 Gbit/s) compared to the previous version of DisplayPort (1.4a), as well as new capabilities to address the future performance requirements of traditional displays. These include beyond 8K resolutions, higher refresh rates and high dynamic range (HDR) support at higher resolutions, improved support for multiple display configurations, as well as improved user experience with augmented/virtual reality (AR/VR) displays, including support for 4K-and-beyond VR resolutions. According to a roadmap published by VESA in September 2016, a new version of DisplayPort was intended to be launched in "early 2017". It would have improved the link rate from 8.1 to 10.0 Gbit/s, a 23% increase. This would have increased the total bandwidth from 32.4 Gbit/s to 40.0 Gbit/s. However, no new version was released in 2017, likely delayed to make further improvements after the HDMI Forum announced in January 2017 that their next standard (HDMI 2.1) would offer up to 48 Gbit/s of bandwidth. According to a press release on 3 January 2018, "VESA is also currently engaged with its members in the development of the next DisplayPort standard generation, with plans to increase the data rate enabled by DisplayPort by two-fold and beyond.
== Epidemiology == Between 0.1% and 0.8% of people are affected. The disease is most common in Northern European countries, and per observations in the UK, is least frequently seen in people of Afro-Caribbean descent. Although the ratio of male to female disease is reportedly 3:1, many rheumatologists believe the number of women with AS is underdiagnosed, as most women tend to experience milder cases of the disease. The majority of people with AS, including 95 per cent of people of European descent with the disease, express the HLA-B27 antigen and high levels of immunoglobulin A (IgA) in the blood. In 2007, a team of researchers discovered two genes that may contribute to the cause of AS: ARTS-1 and IL23R. Together with HLA-B27, these two genes account for roughly 70 percent of the overall number of cases of the disease.
Psilocybe cubensis grows naturally in tropical and subtropical conditions, often near cattle due to the ideal conditions they provide for the growth of the fungus. The cow usually consumes grains or grass covered with the spores of P. cubensis and the fungus will begin to germinate within the dung. Mushrooms such as Psilocybe cubensis are relatively easy to cultivate indoors. First, spores are inoculated within sterilized jars or bags, colloquially known as grainspawn, containing a form of carbohydrate nutrient such as rye or milo gains. After approximately one month, the spores fully colonize the grain spawn forming dense mycelium, which is then mixed within a bulk substrate such as a coconut husk fiber and vermiculite mixture. Given proper humidity, temperature, and fresh air exchange, the substrate will produce fruiting Psilocybe cubensis bodies within a month of planting. To preserve potency after harvesting, growers often dehydrate the fruit and store them in air-tight containers in cool environments. A study conducted in 2009 showed that mushrooms grown in the dark had higher levels of psilocybin and psilocin compared to the mushrooms grown in bright, indirect light, which had minimum levels. Studies were conducted where an environmentally controlled wind tunnel and a computer program were used to determine the influence of humidity on the individual basidiocarps of P. cubensis which aided in mapping their growth and development.
Antihyperlipidemic agents are drugs used for the treatment of dyslipidemia, a condition of abnormal lipid levels in the body. It is characterised by elevations of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) in the blood. Hypercholesterolaemia induces the formation of plaques due to the buildup of excess cholesterol within the arterial wall. This increases the risk of, or aggravate, atherosclerotic cardiovascular disease (ASCVD). Therefore, antihyperlipidemic drugs are introduced for primary and secondary coronary heart disease prevention, as well as for reduction in mortality from acute coronary outcomes. These drugs include statins, ezetimibe and fibrates.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.